Canterbury DHB

Context

March 2015

don't forget to update the issue and next review variables!!!

Changes in this release

Topic or section

Brief description

Reviewer

Prescription Charts

The following charts have been replaced under Chronic Lymphocytic Leukaemia:

  • Rituximab/Cyclo/Fludarabine 375 IV
  • Rituximab/Cyclo/Fludarabine 375 PO
  • Rituximab/Cyclo/Fludarabine 500 IV
  • Rituximab/Cyclo/Fludarabine 500 PO

The following charts have been replaced under Non Hodgkin Lymphoma:

  • R-CVP
  • R-CHOP
  • R-FCM
  • Fractionated R-ICE G
  • Mantle cell Maxi-CHOP (replaces Maxi-CHOP Cycle 1, and Maxi-CHOP Cycle 3+)
  • Mantle cell Maxi HDcytarabine (replaces Maxi-CHOP Rituximab and HD Cytarabine, and Maxi-CHOP Rituximab and HD Cytarabine Stem Cell Mobilisation)
  • R-Hyper-CVAD
  • R-MTX Ara-C
  • CODOX-M - patients 65 years or less
  • CODOX-M - patients over 65
  • R IVAC - patients 65 years or less
  • R IVAC - patients over 65
  • Rituximab 375
  • Ritux hyper-CVAD cycles 1 and 3
  • Ritux MTX cytarabine cycles 2 and 4

The following new chart has been added to Non Hodgkin Lymphoma:

  • R-CEOP

The following new charts have been added under Waldenstroms:

  • Rituximab cladribine daily SC
  • Rituximab fludarabine PO

Jenny Roberts

Myelodysplasia

Assessment of Prognosis was updated.

New information was added on:

Emma-Jane McDonald

Veno Occlusive Disease of the Liver

This sub-section was reviewed and updated.

Andrew Butler

About this Canterbury DHB document (154602):

Document Owner:

Not assigned (see Who's Who)

Issue Date:

Next Review:

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 154602